Literature DB >> 9372880

A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum.

S D Mikolajczyk1, L S Grauer, L S Millar, T M Hill, A Kumar, H G Rittenhouse, R L Wolfert, M S Saedi.   

Abstract

OBJECTIVES: Prostate-specific antigen (PSA) is a widely used serum marker for human prostate cancer (PCa). The majority of PSA in serum is present as a complex with alpha-1-antichymotrypsin (ACT). In recent years, the ratio of free (uncomplexed) to total PSA has shown improved discrimination of PCa from benign prostatic hyperplasia. This study examines the nature of the free PSA from detected in PCa serum and shows that some of the uncomplexed PSA is an inactive precursor of PSA (pPSA).
METHODS: Western blot analysis was used to detect clipped, fragment forms of PSA in sera and seminal fluid. Hydrophobic interaction chromatography-high performance liquid chromatography (HIC-HPLC) was used to identify forms of PSA present in the free PSA population. Pooled sera was passed over a PSA immunoaffinity column, and the eluted PSA components were further resolved by HIC-HPLC.
RESULTS: Western blot analysis of whole sera showed complexed PSA and the intact, approximately 34 kilodalton free PSA. Only negligible levels of clipped or degraded forms of PSA, as found in seminal fluid, were detected. Column fractions measured for uncomplexed PSA using the Tandem-MP free PSA assay showed that about 25% of the free PSA eluted as pPSA beginning at the [-4]amino acid. Studies with purified recombinant [-4]pPSA showed that this proenzyme form is inactive and does not complex with ACT.
CONCLUSIONS: These results suggest that the uncomplexed PSA in PCa serum is primarily unclipped PSA that contains a significant fraction of pPSA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9372880     DOI: 10.1016/S0090-4295(97)00449-4

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  24 in total

1.  [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.

Authors:  Brian V Le; Christopher R Griffin; Stacy Loeb; Gustavo F Carvalhal; Donghui Kan; Nikola A Baumann; William J Catalona
Journal:  J Urol       Date:  2010-02-19       Impact factor: 7.450

2.  Evolving Role of Pro-PSA as a New Serum Marker for the Early Detection of Prostate Cancer.

Authors:  Masood A Khan; Alan W Partin
Journal:  Rev Urol       Date:  2002

3.  Twenty Years of PSA: From Prostate Antigen to Tumor Marker.

Authors:  Gabriela De Angelis; Harry G Rittenhouse; Stephen D Mikolajczyk; L Blair Shamel; Axel Semjonow
Journal:  Rev Urol       Date:  2007

Review 4.  Prostate kallikrein markers in diagnosis, risk stratification and prognosis.

Authors:  David Ulmert; M Frank O'Brien; Anders S Bjartell; Hans Lilja
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

5.  Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples.

Authors:  Akos Végvári; Melinda Rezeli; Jari Häkkinen; Carina Sihlbom; Elisabet Carlsohn; Johan Malm; Hans Lilja; Thomas Laurell; György Marko-Varga
Journal:  J Proteomics       Date:  2011-06-23       Impact factor: 4.044

6.  Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry.

Authors:  Ákos Végvári; Melinda Rezeli; Carina Sihlbom; Jari Häkkinen; Elisabet Carlsohn; Johan Malm; Hans Lilja; Thomas Laurell; György Marko-Varga
Journal:  Clin Biochem       Date:  2011-12-16       Impact factor: 3.281

Review 7.  [Value of biomarkers in urology].

Authors:  P J Goebell; B Keck; S Wach; B Wullich
Journal:  Urologe A       Date:  2010-04       Impact factor: 0.639

8.  A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

Authors:  William J Catalona; Alan W Partin; Martin G Sanda; John T Wei; George G Klee; Chris H Bangma; Kevin M Slawin; Leonard S Marks; Stacy Loeb; Dennis L Broyles; Sanghyuk S Shin; Amabelle B Cruz; Daniel W Chan; Lori J Sokoll; William L Roberts; Ron H N van Schaik; Isaac A Mizrahi
Journal:  J Urol       Date:  2011-03-17       Impact factor: 7.450

Review 9.  Aberrant PSA glycosylation--a sweet predictor of prostate cancer.

Authors:  Sarah Gilgunn; Paul J Conroy; Radka Saldova; Pauline M Rudd; Richard J O'Kennedy
Journal:  Nat Rev Urol       Date:  2013-01-15       Impact factor: 14.432

Review 10.  Analysis of protein isoforms: can we do it better?

Authors:  Miroslava Stastna; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2012-09-19       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.